Aimovig (erenumab-aooe) works to help prevent chronic migraine headaches by blocking the activity of calcitonin gene-related peptide (CGRP), a molecule that is involved in migraine attacks and rises during an attack. The calcitonin gene-related peptide (CGRP) receptor antagonists are a new class of drugs for migraine. Aimovig, from Amgen, is also the first fully human monoclonal antibody for migraine prevention. This treatment for adults is given once-a-month by subcutaneous (under the skin) self-injections with an auto-injector type pen or a single-dose prefilled syringe.
Subscribe to receive email notifications whenever new articles are published.
Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include IBM Watson Micromedex (updated 9 Jan 2019), Cerner Multum™ (updated 14 Jan 2019), Wolters Kluwer™ (updated 7 Jan 2019) and others. Refer to our editorial policy for content sources and attributions.